Inventor

Eckard Weber

Inventor

Laguna Beach, CA, US

Overview

1984–2019

Patent span

Human necessities

Primary field (CPC A)

Patents· 71 as inventor

Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.

A61Kprimary

A61KPreparations for medical, dental or toiletry purposes28%

A61PSpecific therapeutic activity of chemical compounds or medicinal preparations20%

C07DHeterocyclic compounds19%

C07CAcyclic or carbocyclic compounds13%

C07BGeneral methods of organic chemistry5%

Y10STechnical subjects covered by former uspc cross-reference art collections [xracs] and digests4%

C07KPeptides3%

A61JContainers specially adapted for medical or pharmaceutical purposes2%

B65DContainers for storage or transport of articles or materials, e.g. bags, barrels, bottles, boxes, cans, cartons, crates, drums, jars, tanks, hoppers, forwarding containers2%

C12QMeasuring or testing processes involving enzymes, nucleic acids or microorganisms2%

PatentTitleYear

10,307,376Methods for administering weight loss medications2019 10,238,647Compositions for affecting weight loss2019 9,125,868'Methods for administering weight loss medications'2015 8,722,085'Methods for administering weight loss medications'2014 8,318,788'Layered pharmaceutical formulations'2012 8,088,786'Layered pharmaceutical formulations'2012 7,575,757'Stabilized formulations of alpha adrenergic receptor antagonists and the uses thereof'2009 7,569,230'Stabilized formulations of alpha adrenergic receptor antagonists and the uses thereof'2009 7,462,626'Compositions for affecting weight loss'2008 7,375,111'Compositions for affecting weight loss'2008 7,270,801'Fluorogenic or fluorescent reporter molecules and their applications for whole-cell fluorescence screening assays for caspases and other enzymes and the use thereof'2007 7,261,889'Local anesthetic methods and kits'2007 7,229,630'Stabilized formulations of alpha adrenergic receptor antagonists and the uses thereof'2007 6,949,516'Dipeptide apoptosis inhibitors and the use thereof'2005 6,872,390'Local anesthetic methods and kits'2005 6,764,678'Local anesthetic methods and kits'2004 6,759,207'Fluorogenic or fluorescent reporter molecules and their applications for whole-cell fluorescence screening assays for caspases and other enzymes and the use thereof'2004 6,716,818'Caspase inhibitors and the use thereof'2004 6,613,803'Carbocyclic and heterocyclic substituted semicarbazones and thiosemicarbazones and the use thereof'2003 6,596,693'Dipeptide apoptosis inhibitors and the thereof'2003 6,566,338'Caspase inhibitors for the treatment and prevention of chemotherapy and radiation therapy induced cell death'2003 6,534,525'2-substituted piperidine analogs and their use as subtype-selective NMDA receptor antagonists'2003 6,495,522'Substituted alpha-hydroxy acid caspase inhibitors and the use thereof'2002 6,458,843'Carbocyclic and heterocyclic substituted semicarbazones and thiosemicarbazones and the use thereof'2002 6,448,270'4-substituted piperidine analogs and their use as subtype selective NMDA receptor antagonists'2002 6,432,401'Local anesthetic methods and kits'2002 6,355,618'Caspase inhibitors and the use thereof'2002 6,342,611'Fluorogenic or fluorescent reporter molecules and their applications for whole-cell fluorescence screening assays for capsases and other enzymes and the use thereof'2002 6,251,948'Tri-and tetra-substituted guanidines and their use as excitatory amino acid antagonists'2001 6,251,903'Alkyl, azido, alkoxy, and fluoro-substituted and fused quinoxalinediones and the use thereof as glycine receptor antagonist'2001 6,153,591'Dipeptide caspase inhibitors and the use thereof'2000 6,147,075'Alkyl, azido, alkoxy and fluoro-substituted and fused quinoxalinediones and the use thereof as glycine receptor antagonist'2000 6,130,234'4-substituted piperidine analogs and their use as subtype selective NMDA receptor antagonists'2000 6,124,323'4-substituted piperidine analogs and their use as subtype selective NMDA receptor antagonists'2000 6,124,317'2-substituted piperidine analogs and their use as subtype-selective NMDA receptor antagonists'2000 6,017,910'PCP receptor ligands and the use thereof'2000 5,977,107'Alkyl, azido, alkoxy, and fluoro-substituted and fused quinoxalinediones and the use thereof as glycine receptor antagonists'1999 5,863,916'8-aza, 6-aza and 6,8-diaza-1,4-dihydroquinoxaline-2,3-diones and the use thereof as antagonists for the glycine/NMDA receptor'1999 5,798,390'Tri- and tetra-substituted guanidines and their use as excitatory amino acid antagonists'1998 5,767,162'Tri-and tetra-substituted guanidines and their use as excitatory amino acid antagonists'1998 5,688,789'PCP receptor ligands and the use thereof'1997 5,652,368'1,2,3,4-tetrahydroquinoline 2,3,4-trione-3 or 4-oximes'1997 5,637,622'Tri- and tetra-substituted guanidines and their use as excitatory amino acid antagonists'1997 5,631,373'Alkyl, azido, alkoxy, and fluoro-substituted and fused quinoxalinediones'1997 5,622,965'4-hydroxy-3-nitro-1,2-dihydroquinolin-2-ones and the use thereof as excitatory amino acid and glycine receptor antagonists'1997 5,622,952'Glycine receptor antagonists and the use thereof'1997 5,620,979'Glycine receptor antagonists and the use thereof'1997 5,620,978'8-aza, 6-aza and 6,8-diaza-1,4-dihydroquinoxaline-2,3-diones and the use thereof as antagonists for the glycine/NMDA receptor'1997 5,604,228'Substituted guanidines having high binding to the sigma receptor and the use thereof'1997 5,597,922'Glycine receptor antagonist pharmacophore'1997 5,574,070'Substituted guanidines having high binding to the sigma receptor and the use thereof'1996 5,559,154'Tri- and tetra-substituted guanidines and their use as excitatory amino acid antagonists'1996 5,552,443'Substituted amidines having high binding to the sigma receptor and the use thereof'1996 5,514,680'Glycine receptor antagonists and the use thereof'1996 5,502,255'Substituted guanidines having high binding to the sigma receptor and the use thereof'1996 5,478,863'Substituted guanidines having high binding to the sigma receptor and the use thereof'1995 5,475,007'1,2,3,4-tetrahydroquinoline-2,3,4-trione-3 or 4-oximes and the use thereof'1995 5,385,946'Method for treating hypertension with disubstituted granidine compounds'1995 5,336,689'Tri- and tetra-substituted guanidines and their use as excitatory amino acid antagonists'1994 5,312,840'Substituted guanidines having high binding to the sigma receptor and the use thereof'1994 5,308,869'Substituted amidines having high binding to the sigma receptor and the use thereof'1994 5,262,568'Tri- and tetra-substituted guanidines and their use as excitatory amino acid antagonists'1993 5,190,976'N,N\'-disubstituted guanidines and their use as excitatory amino acid antagonists'1993 5,093,525'N,N\'-disubstituted guanidines and their use as excitatory amino acid antagonists'1992 5,011,834'PCP receptor ligands and the use thereof'1991 4,975,430'CNQX and its analogs as therapeutics for degenerative neural diseases'1990 4,906,779'N,N\'-disubstituted guanidines and their use as excitatory amino acid antagonists'1990 4,709,094'Sigma brain receptor ligands and their use'1987 4,613,586'Gastrin releasing peptide-like peptides'1986 4,587,233'Use of Arg-Phe-amide derivatives'1986 4,490,363'Metorphamide--a novel morphine-like peptide'1984

Career & activity timeline

Assembled from patent assignee/location history and declaration credentials.

1984–1986Based in Palo Alto, CA, US· patent location history

1986Based in San Francisco, CA, US· patent location history

1987–2001Patents assigned to OREGON STATE (35)· patent assignee history

1987–1996Based in Portland, OR, US· patent location history

1992–2003Based in Laguna Beach, CA, US· patent location history

1995–2001Patents assigned to UNIV CALIFORNIA (13)· patent assignee history

1999–2003Patents assigned to COCENSYS INC (9)· patent assignee history

2000–2007Patents assigned to CYTOVIA INC (10)· patent assignee history

2000–2019Based in San Diego, CA, US· patent location history

2002–2009Patents assigned to NOVALAR PHARMACEUTICALS INC (7)· patent assignee history

Inventor activity

Assignee and location history derived from the patent record.

Assignees

Assignee	Patents	Span
OREGON STATE	35	1987–2001
UNIV CALIFORNIA	13	1995–2001
CYTOVIA INC	10	2000–2007
COCENSYS INC	9	1999–2003
NOVALAR PHARMACEUTICALS INC	7	2002–2009

Locations

Location	Patents	Span
Laguna Beach, California, US	33	1992–2003
San Diego, California, US	27	2000–2019
Portland, OR, US	8	1987–1996
Palo Alto, California, US	2	1984–1986
San Francisco, California, US	1	1986